A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 19 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
- 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2016 Planned primary completion date changed from 1 Sep 2018 to 1 Jul 2018.